- ►annals.org JJ Molldrem, E Leifer, E Bahceci, Y … - Annals of internal medicine, 2002 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Background: Almost half of the deaths that result from myelodysplastic ... Cited by 133 - Related articles - BL Direct - All 4 versions
SB Killick, G Mufti, JD Cavenagh, A Mijovic … - British journal of haematology, 2003 - pt.wkhealth.com Sally B. Killick, 1 Ghulam Mufti, 2 Jamie D. Cavenagh, 3 Alex Mijovic, 2 Janet
L. Peacock, 4 ... Edward C. Gordon-Smith, 1 David T. Bowen 5 and Judith CW
Marsh 1 1Department of Haematology, ... St George's Hospital, 2Department ... Cited by 76 - Related articles - BL Direct - All 6 versions
- ►bloodjournal.org Y Saunthararajah, R Nakamura, R Wesley, QJ … - Blood, 2003 - Am Soc Hematology Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be
used to treat the cytopenia associated with myelodysplastic syndrome (MDS).
Previously, we identified HLA-DR15, younger age, and shorter duration of ... Cited by 80 - Related articles - BL Direct - All 5 versions
- ►hematologylibrary.org Y Saunthararajah, R Nakamura, JM Nam, J … - Blood, 2002 - bloodjournal.hematologylibrary.org Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized
by bone marrow failure, marrow dysplasia, and a tendency to evolve to acute
leukemia. There is accumulating evidence that T-cell-mediated immune ... Cited by 135 - Related articles - BL Direct - All 4 versions
- ►bloodjournal.org [PDF] DP Steensma, A Dispenzieri, SB Moore, G … - Blood, 2003 - Am Soc Hematology The myelodysplastic syndrome (MDS) includes a heterogeneous group of marrow
disorders characterized by ineffective hematopoi- esis and a variable risk of
leukemic transformation. Because most patients with MDS are diagnosed after ... Cited by 55 - Related articles - All 6 versions
S Yazji, FJ Giles, AM Tsimberidou, EH Estey, … - Leukemia, 2003 - nature.com The purpose of this study was to determine the efficacy of and tolerance to
antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic
syndrome (MDS). Therapy consisted of ATG 40 mg/kg/day daily intravenously ... Cited by 37 - Related articles - BL Direct - All 3 versions
M Stadler, U Germing, KO Kliche, KM Josten, … - Leukemia, 2004 - nature.com Immunosuppression has recently been proposed for low-risk myelodysplastic
syndromes (MDS) to reverse bone marrow failure by inhibiting intramedullary
secretion of proapoptotic cytokines. We treated 35 MDS patients (24 ... Cited by 52 - Related articles - All 3 versions
- ►hematologylibrary.org JN Kochenderfer, S Kobayashi, ED Wieder, C … - Blood, 2002 - bloodjournal.hematologylibrary.org To investigate whether dominant T-cell clones are present in patients with MDS,
we studied 12 patients with cytopenia who were enrolled in a randomized clinical
trial of ATG, ATG plus fludarabine, or ATG plus cyclosporine. We ... Cited by 71 - Related articles - BL Direct - All 5 versions
A JonÁšovÁ, R NeuwirtovÁ, J CermAk, V … - Br J Haematol, 1998 - interscience.wiley.com We report 17 cytopenic patients with myelodysplastic syndrome (MDS) of
refractory anaemia (RA) subtype with hyper-, normo- or hypo-cellular bone marrow
(BM), who were treated with cyclosporin A (CyA). Substantial haematological ... Cited by 199 - Related articles - BL Direct - All 4 versions
JJ Molldrem, M Caples, D Mavroudis, M Plante … - British Journal of Haematology, 1997 - interscience.wiley.com Twenty-five transfusion-dependent myelodysplastic syndrome (MDS) patients (with
< 20% blasts) were treated in a phase II study with antithymocyte globulin (ATG)
at 40 mg/kg/d for four doses and then followed with blood counts every 2 ... Cited by 217 - Related articles - BL Direct - All 4 versions
